ArticlePediatric research2026
F-NEO-BRIGHT: feasibility and safety of intranasal fresh breast milk in neonatal encephalopathy.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypoxic-ischemic encephalopathy (HIE) remains a major cause of neonatal mortality and long-term neurodevelopmental disability. Intranasally delivered mesenchymal stem cells and neurotrophic factors from breast milk have been detected in the central nervous system and may have a role in neuroregenerative processes. F-NEO-BRIGHT (Feasibility- NEOnatal- intranasal BReast milk, Impact on brain Growth in HIE Therapy) is the first clinical study aimed to assess the feasibility and safety of intranasal fresh breast milk (iFBM) in neonates with HIE in both inpatient and home settings.
methodsThis prospective, single-center study involved ten patients diagnosed with moderate to severe HIE treated with therapeutic hypothermia. Own-mother's fresh breast milk expressed within 4 h, was given intranasally twice daily, 0.4 ml in each nostril, initiated within 48 h of life and continued until day 28.
resultsUnder continuous cardiorespiratory and neurointensive monitoring in neonatal intensive care, the therapy was well tolerated with no adverse events or side effects observed. The intervention proved to be feasible, treatment initiation was achieved within 48 h in all enrolled neonates and was successfully continued by parents in the home setting.
conclusioniFBM in neonates with moderate to severe HIE is safe and feasible in both inpatient and home settings. IMPACT: F-NEO -BRIGHT Study is the first clinical trial where intranasal fresh breast milk is administered to neonates with neonatal encephalopathy. Intranasal fresh breast milk administration during the first month of life appears to be feasible, safe and well-tolerated both in hospital and in the home settings. The full therapeutic potential of this treatment could be revealed by further research into long-term neurodevelopmental outcomes.
Identifiers
41776367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.